Mutual of America Capital Management LLC Sells 1,654 Shares of Edwards Lifesciences Co. (NYSE:EW)

Mutual of America Capital Management LLC trimmed its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 79,701 shares of the medical research company’s stock after selling 1,654 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Edwards Lifesciences were worth $7,616,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the stock. Daiwa Securities Group Inc. raised its holdings in Edwards Lifesciences by 11.1% in the 1st quarter. Daiwa Securities Group Inc. now owns 73,980 shares of the medical research company’s stock worth $7,070,000 after purchasing an additional 7,410 shares during the period. Graypoint LLC bought a new position in Edwards Lifesciences in the 1st quarter worth $337,000. Pittenger & Anderson Inc. raised its holdings in Edwards Lifesciences by 57.0% in the 1st quarter. Pittenger & Anderson Inc. now owns 10,705 shares of the medical research company’s stock worth $1,023,000 after purchasing an additional 3,887 shares during the period. Nordea Investment Management AB raised its holdings in Edwards Lifesciences by 32.7% during the first quarter. Nordea Investment Management AB now owns 2,136,986 shares of the medical research company’s stock valued at $202,928,000 after acquiring an additional 526,574 shares during the period. Finally, Waycross Partners LLC raised its holdings in Edwards Lifesciences by 9.0% during the first quarter. Waycross Partners LLC now owns 134,470 shares of the medical research company’s stock valued at $12,850,000 after acquiring an additional 11,149 shares during the period. 79.46% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Bernard J. Zovighian acquired 580 shares of the firm’s stock in a transaction dated Monday, May 6th. The stock was acquired at an average price of $85.74 per share, with a total value of $49,729.20. Following the acquisition, the chief executive officer now directly owns 3,268 shares in the company, valued at approximately $280,198.32. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Bernard J. Zovighian sold 8,617 shares of Edwards Lifesciences stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $87.68, for a total value of $755,538.56. Following the completion of the transaction, the chief executive officer now owns 68,218 shares in the company, valued at approximately $5,981,354.24. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Bernard J. Zovighian purchased 580 shares of the business’s stock in a transaction that occurred on Monday, May 6th. The stock was acquired at an average price of $85.74 per share, with a total value of $49,729.20. Following the purchase, the chief executive officer now owns 3,268 shares in the company, valued at $280,198.32. The disclosure for this purchase can be found here. Insiders sold a total of 76,099 shares of company stock valued at $6,537,103 in the last quarter. 1.27% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

EW traded down $0.46 on Monday, reaching $91.86. 1,941,251 shares of the stock were exchanged, compared to its average volume of 3,417,075. The company’s 50-day moving average price is $88.33 and its 200 day moving average price is $86.03. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. The firm has a market capitalization of $55.35 billion, a PE ratio of 39.59, a PEG ratio of 3.38 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. As a group, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on EW shares. Citigroup raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price target for the company from $98.00 to $105.00 in a report on Wednesday, May 22nd. Wells Fargo & Company raised their price target on Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a report on Friday, April 26th. Morgan Stanley raised their price objective on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. Barclays lifted their price target on Edwards Lifesciences from $100.00 to $101.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 7th. Finally, Deutsche Bank Aktiengesellschaft raised Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $86.00 to $103.00 in a research note on Tuesday, May 14th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average target price of $95.18.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.